Because the FFAR4 agonist has received increasing attention as attractive pharmaceutical agents for type 2 diabetes [35, 36], our findings may provide new and important insights into the development of novel FFAR4 ligands. Here, FFAR4 is linked to type 2 diabetes mellitus.